Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide and is of great commercial importance.  With over 20 million new strands of cancer predicted to evolve in 2025, (according to the WHO), it corresponds that research devoted to improving the treatment of oncology is set to increase exponentially.

Optimizing trial development in order to speed approval time and improve operational efficiency continues to be one of the major themes being discussed at Fleming Europe’s 2nd Annual Clinical Trials in Oncology Conference which is once again bringing you two days of ground-breaking debate and pioneering case-studies from top industry, regulatory and association experts.

This unique event offers participants the opportunity to meet and discuss current issues as well as network  with over 15 high profile speakers and panellists from across Europe, North America and Asia and many more participants.

Attend this event to explore effective strategies to gain competitive advantage and understand the role of safety biomarkers in clinical development. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on optimizing trial development in order to speed approval time and improve operational efficiency.

Chief Clinical Officers, Senior Vice Presidents, Vice presidents, global heads, heads, directors, senior managers, managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging